Treating Patients With Prostate Cancer During COVID-19 Era Poses New Challenges
Monica L. Baskin, PhD, addresses the biggest challenges in treating patients with prostate cancer during the COVID-19 era.
Monica L. Baskin, PhD, professor, Division of Preventive Medicine, vice chair for culture and diversity, Department of Medicine, associate director, Community Outreach and Engagement, O’Neal Comprehensive Cancer Center, The University of Alabama at Birmingham, addresses the biggest challenges in treating patients with prostate cancer during the coronavirus disease 2019 (COVID-19) era.
The biggest challenge is moving beyond the patient’s anxiety of coming into the clinic or getting involved at healthcare facilities due to concerns of COVID-19, according to Baskin. It’s important to balance these concerns with the patient’s ongoing need for treatment.
Baskin notes that many cases in prostate cancer are slow growing, in which case patients can wait for treatment. However, some patients are reluctant to complete screening and treating due to the COVID-19 pandemic. This is a challenge for many physicians, and it is important to move forward with cancer treatment and to do so in a safe manner, Baskin concludes.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
